Clascoterone is an androgen receptor inhibitor developed as a cream and solution for the treatment of androgen-dependent skin disorders, including androgenetic alopecia and acne vulgaris.

In August 2020, 1% clascoterone cream received its first approval in the United States for the topical treatment of acne vulgaris in patients 12 years of age and older. Clinical trials are ongoing in Germany and the United States on a different formulation containing a higher concentration of clascoterone.

Chemelectiva owns an innovative and efficient technology for the synthesis of clascoterone.